{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:02:52Z","timestamp":1784289772900,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To facilitate equitable access to novel treatments, cancer trial participants should represent as far as possible those that will receive the treatment in practice. We can identify groups who rarely participate in cancer trials by collecting demographic data from participants. In the UK, there is no standardised practice around demographic data capture, leading to inconsistent collection across trials. A lack of systematically collected and published quantitative data from participants in UK cancer trials may limit our ability to identify underrepresented groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed availability and completeness of demographic data recorded from 2235 participants in six bladder and six head and neck cancer trials conducted by the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU) between 2001 and 2023. To assess the representativeness of trial populations, demographic data from trial participants were compared with published data (NHS Digital) from 260,350 people who were treated for these cancers between 2013 and 2022 in England, using chi-squared goodness-of-fit tests and one-sample tests of proportion. A survey was distributed to 12 clinical trials units conducting similar trials to establish which demographic data are routinely collected across the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data on ethnicity, postcode, smoking status, and co-morbidity burden were inconsistently captured across ICR-CTSU trials, with missing data. Amongst the overall trial population, people older than 80 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009486\/2235, 22%), females (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009466\/2235, 21%), people living in the most deprived areas (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009390\/1447, 27%), and ethnic minority groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095\/275, 2%) were underrepresented, with some differences by treatment modality. Responses from UK trial teams showed that aside from age and sex (routinely captured), smoking status was the most consistently captured (13\/17 trials).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides quantitative data on cancer trial participants examining several demographic factors and indicates potentially underrepresented groups in trials of the disease subtypes investigated. Missing data were likely observed as a result of data cleaning being focused on items directly addressing the research question. Collecting and analysing a broad range of demographic data with a focus on inclusivity can inform researchers of groups who may benefit from tailored interventions to increase accessibility to cancer trials in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09812-2","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:05:05Z","timestamp":1779541505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying underrepresented groups in oncology clinical trials using routinely collected data in an English academic trial setting"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-6604","authenticated-orcid":false,"given":"Georgiana","family":"Synesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Kilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"9812_CR1","volume-title":"Improving representativeness in clinical trials and research: facilitators to recruitment and retention of underrepresented groups","author":"F Arias","year":"2022","unstructured":"Arias F, Rogus-Pulia N, Kind AJH. Improving representativeness in clinical trials and research: facilitators to recruitment and retention of underrepresented groups. Washington (DC): National Academies Press (US); 2022."},{"issue":"14","key":"9812_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMp2215609","volume":"388","author":"AL Schwartz","year":"2023","unstructured":"Schwartz AL, Alsan M, Morris AA, Halpern SD. Why diverse clinical trial participation matters. N Engl J Med. 2023;388(14):1252\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"9812_CR3","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/bcp.15242","volume":"88","author":"AS Gross","year":"2022","unstructured":"Gross AS, Harry AC, Clifton CS, Della Pasqua O. Clinical trial diversity: an opportunity for improved insight into the determinants of variability in drug response. Br J Clin Pharmacol. 2022;88(6):2700\u201317.","journal-title":"Br J Clin Pharmacol"},{"key":"9812_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.socscimed.2014.05.021","volume":"127","author":"JP Mackenbach","year":"2015","unstructured":"Mackenbach JP, Kulh\u00e1nov\u00e1 I, Bopp M, Deboosere P, Eikemo TA, Hoffmann R, et al. Variations in the relation between education and cause-specific mortality in 19 European populations: a test of the \u201cfundamental causes\u201d theory of social inequalities in health. Soc Sci Med. 2015;127:51\u201362.","journal-title":"Soc Sci Med"},{"key":"9812_CR5","unstructured":"NIHR. Improving inclusion of under-served groups in clinical research: guidance from INCLUDE project 2020 [Available from: https:\/\/www.nihr.ac.uk\/documents\/improving-inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project\/25435."},{"issue":"1","key":"9812_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12910-023-00987-w","volume":"24","author":"D Patel","year":"2023","unstructured":"Patel D, Kilburn L, Fox L, Hall E, Bliss J, Lewis R. Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting. BMC Med Ethics. 2023;24(1):105.","journal-title":"BMC Med Ethics"},{"key":"9812_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-026-00836-1","author":"E Lidington","year":"2026","unstructured":"Lidington E, Stiles M, Maudsley J, Ching J, Deutsch A, Lipman N, et al. Establishing a set of acceptable demographic questions for use in health research through public consultation. Res Involv Engagem. 2026;12(1).\u00a0https:\/\/doi.org\/10.1186\/s40900-026-00836-1.","journal-title":"Res Involv Engagem"},{"key":"9812_CR8","unstructured":"Gov.UK. Equality Act 2010. 2010. from https:\/\/www.legislation.gov.uk\/ukpga\/2010\/15\/contents."},{"key":"9812_CR9","unstructured":"NIHR. Randomised controlled trial participants: diversity data report: NIHR; 2022 [Available from: https:\/\/www.nihr.ac.uk\/documents\/randomised-controlled-trial-participants-diversity-data-report\/31969#report-highlights."},{"key":"9812_CR10","volume-title":"Accounting for sex and gender in biomedical, health and care research: a policy framework for UK research funders","author":"A Witt","year":"2024","unstructured":"MESSAGE Writing Group, Witt A, Woodward M, Jenkins K, Jenkins B, Hockham C. Accounting for sex and gender in biomedical, health and care research: a policy framework for UK research funders. Medical Science Sex and Gender Equity; 2024."},{"issue":"7","key":"9812_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL, Committee AMoS. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326(7):621\u20137.","journal-title":"JAMA"},{"issue":"8","key":"9812_CR12","doi-asserted-by":"publisher","first-page":"e2416646","DOI":"10.1001\/jama.2024.16646","volume":"332","author":"A Flanagin","year":"2024","unstructured":"Flanagin A, Frey T, Christiansen S, Bibbins-Domingo K. Draft guidance on reporting gender, sex, gender identity, sexual orientation, and age in medical and scientific publication\u2014call for review and comment. JAMA. 2024;332(8):e2416646-e.","journal-title":"JAMA"},{"issue":"1","key":"9812_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/13557858.2016.1182126","volume":"22","author":"A Smart","year":"2017","unstructured":"Smart A, Harrison E. The under-representation of minority ethnic groups in UK medical research. Ethn Health. 2017;22(1):65\u201382.","journal-title":"Ethn Health"},{"key":"9812_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100939","volume":"28","author":"G Kumar","year":"2022","unstructured":"Kumar G, Chaudhary P, Quinn A, Su D. Barriers for cancer clinical trial enrollment: a qualitative study of the perspectives of healthcare providers. Contemp Clin Trials Commun. 2022;28:100939.","journal-title":"Contemp Clin Trials Commun"},{"issue":"33","key":"9812_CR15","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol. 2017;35(33):3737\u201344.","journal-title":"J Clin Oncol"},{"key":"9812_CR16","unstructured":"Clinical trials in cancer: barriers in access to clinical trials, especially in light of the COVID-19 pandemic. The Institute of Cancer Research; 2021.\u00a0from https:\/\/www.icr.ac.uk\/docs\/default-source\/migrated-documents\/corporate-docs--accounts--and-annual-reports\/icr-report-clinical-trials-in-cancer.pdf?sfvrsn=d6a98401_2."},{"key":"9812_CR17","unstructured":"Estimates of the population for the UK, England, Wales, Scotland and Northern Ireland: The Office of National Statistics; 2017\u20132021 [Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland."},{"key":"9812_CR18","unstructured":"Cancer registration statistics, England: NHS Digital; 2022 [Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics."},{"issue":"6","key":"9812_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jme.2009.033845","volume":"36","author":"S Godden","year":"2010","unstructured":"Godden S, Ambler G, Pollock AM. Recruitment of minority ethnic groups into clinical cancer research trials to assess adherence to the principles of the Department of Health Research Governance Framework: national sources of data and general issues arising from a study in one hospital trust in England. J Med Ethics. 2010;36(6):358\u201362.","journal-title":"J Med Ethics"},{"key":"9812_CR20","unstructured":"Cancer incidence for common cancers: Cancer Research UK; 2018 [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/common-cancers-compared#heading-Zero."},{"key":"9812_CR21","unstructured":"Bladder cancer incidence statistics: Cancer Research UK; [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer\/incidence#heading-Zero."},{"key":"9812_CR22","unstructured":"Head and neck cancers incidence statistics: Cancer Research UK; [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/head-and-neck-cancers\/incidence#heading-Zero."},{"issue":"12","key":"9812_CR23","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41416-022-01718-5","volume":"126","author":"C Delon","year":"2022","unstructured":"Delon C, Brown KF, Payne NWS, Kotrotsios Y, Vernon S, Shelton J. Differences in cancer incidence by broad ethnic group in England, 2013-2017. Br J Cancer. 2022;126(12):1765\u201373.","journal-title":"Br J Cancer"},{"issue":"8","key":"9812_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","volume":"118","author":"KF Brown","year":"2018","unstructured":"Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130\u201341.","journal-title":"Br J Cancer"},{"issue":"12","key":"9812_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.14740\/jocmr3617w","volume":"10","author":"S Roy","year":"2018","unstructured":"Roy S, Vallepu S, Barrios C, Hunter K. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J Clin Med Res. 2018;10(12):911\u20139.","journal-title":"J Clin Med Res"},{"issue":"7","key":"9812_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","volume":"25","author":"SM Bluethmann","year":"2016","unstructured":"Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the \u201csilver tsunami\u201d: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1029\u201336.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"9812_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0194599818796163","volume":"160","author":"DF Eytan","year":"2019","unstructured":"Eytan DF, Blackford AL, Eisele DW, Fakhry C. Prevalence of comorbidities among older head and neck cancer survivors in the United States. Otolaryngol Head Neck Surg. 2019;160(1):85\u201392.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"9812_CR28","unstructured":"Health survey for England, 2021 part 2. NHS Digital; 2021, 16\/05\/2023.\u00a0from https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2021-part-2\/."},{"key":"9812_CR29","unstructured":"Cancer treatments 2013\u20132022 NHS Digital: NDRS; 2025 [Available from: https:\/\/nhsd-ndrs.shinyapps.io\/cancer_treatments\/."},{"issue":"5","key":"9812_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"9812_CR31","unstructured":"UK Data Service. GeoConvert 2024 [Available from: https:\/\/geoconvert.ukdataservice.ac.uk\/."},{"key":"9812_CR32","unstructured":"The English Index of Multiple Deprivation (IMD) 2015 \u2013 guidance. 2015.\u00a0from https:\/\/assets.publishing.service.gov.uk\/media\/5a7f0e5ded915d74e33f410b\/English_Index_of_Multiple_Deprivation_2015_-_Guidance.pdf."},{"key":"9812_CR33","unstructured":"CAS-SOP v4.9.1 Linking treatment tables: chemotherapy, tumour resections, and radiotherapy: NHS Digital; 2024 [Available from: https:\/\/digital.nhs.uk\/ndrs\/data\/data-outputs\/cancer-data-hub\/cancer-treatments."},{"key":"9812_CR34","unstructured":"Schwabish J, Feng A. Considerations for ensuring data aggregation is as inclusive as possible: Urban Institute; 2022 [Available from: https:\/\/www.urban.org\/urban-wire\/considerations-ensuring-data-aggregation-inclusive-possible."},{"issue":"7","key":"9812_CR35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","volume":"21","author":"JH Lewis","year":"2003","unstructured":"Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9812_CR36","first-page":"78","volume":"71","author":"MS Sedrak","year":"2021","unstructured":"Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78\u201392.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"9812_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/JU9.0000000000000052","volume":"1","author":"H Miyagi","year":"2023","unstructured":"Miyagi H, Bozorgmehri S, Batra NV, Chatzkel JA, Ramnaraign BH, Hitchcock K, et al. Gender disparities in the clinical trials and real-world utilization of systemic therapy in the management of urothelial carcinoma. JU Open Plus. 2023;1(11):e00059.","journal-title":"JU Open Plus"},{"key":"9812_CR38","first-page":"1","volume":"81","author":"Y Remolina","year":"2022","unstructured":"Remolina Y, Caballero-Landinez R, Bourlon M. Women with bladder cancer: an underserved population due to a faulty health care system or in a biological disadvantage? Rev Mex Urol. 2022;81:1\u201311.","journal-title":"Rev Mex Urol"},{"key":"9812_CR39","unstructured":"Raleigh V, Holmes J. The health of people from ethnic minority groups in England: The Kings Fund; 2021 [Available from: https:\/\/www.kingsfund.org.uk\/publications\/health-people-ethnic-minority-groups-england."},{"issue":"953","key":"9812_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/pgmj.2004.026237","volume":"81","author":"A Szczepura","year":"2005","unstructured":"Szczepura A. Access to health care for ethnic minority populations. Postgrad Med J. 2005;81(953):141\u20137.","journal-title":"Postgrad Med J"},{"issue":"8","key":"9812_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064276","volume":"12","author":"SC Buttery","year":"2022","unstructured":"Buttery SC, Philip KEJ, Alghamdi SM, Williams PJ, Quint JK, Hopkinson NS. Reporting of data on participant ethnicity and socioeconomic status in high-impact medical journals: a targeted literature review. BMJ Open. 2022;12(8):e064276.","journal-title":"BMJ Open"},{"key":"9812_CR42","unstructured":"Drummond R. How ethnicity recording differs across health data sources and the impact on analysis: Office for National Statistics; 2023 [Available from: https:\/\/blog.ons.gov.uk\/2023\/01\/16\/how-ethnicity-recording-differs-across-health-data-sources-and-the-impact-on-analysis\/."},{"issue":"1","key":"9812_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamaoncol.2015.3924","volume":"2","author":"JM Unger","year":"2016","unstructured":"Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol. 2016;2(1):137\u20139.","journal-title":"JAMA Oncol"},{"issue":"2","key":"9812_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s10903-010-9410-0","volume":"14","author":"D Silver","year":"2012","unstructured":"Silver D, Blustein J, Weitzman BC. Transportation to clinic: findings from a pilot clinic-based survey of low-income suburbanites. J Immigr Minor Health. 2012;14(2):350\u20135.","journal-title":"J Immigr Minor Health"},{"issue":"12","key":"9812_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.20.02602","volume":"39","author":"JM Unger","year":"2021","unstructured":"Unger JM, Moseley AB, Cheung CK, Osarogiagbon RU, Symington B, Ramsey SD, et al. Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. J Clin Oncol. 2021;39(12):1339\u201348.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9812_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1200\/JCO.2012.45.0999","volume":"31","author":"AM Noor","year":"2013","unstructured":"Noor AM, Sarker D, Vizor S, McLennan B, Hunter S, Suder A, et al. Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol. 2013;31(2):224\u201330.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9812_CR47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41416-024-02765-w","volume":"131","author":"S Rae","year":"2024","unstructured":"Rae S, Shaya S, Taylor E, Hoben J, Oluwashegun D, Lowe H, et al. Social determinants of health inequalities in early phase clinical trials in Northern England. Br J Cancer. 2024;131(4):685\u201391.","journal-title":"Br J Cancer"},{"key":"9812_CR48","unstructured":"Payments and incentives in research: Health Research Authority; 2024 [Available from: https:\/\/www.hra.nhs.uk\/about-us\/committees-and-services\/nreap\/payments-and-incentives-research\/."},{"key":"9812_CR49","unstructured":"Payment guidance for members of the public considering involvement in research: National Institute for Health and Care Research (NIHR); 2024 [Available from: https:\/\/www.nihr.ac.uk\/payment-guidance-members-public-considering-involvement-research."},{"issue":"1","key":"9812_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13063-026-09424-w","volume":"27","author":"G Synesi","year":"2026","unstructured":"Synesi G, Lewis R, Kilburn L, Bliss J, Cheung KC, Gribble H, et al. Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review. Trials. 2026;27(1):19.","journal-title":"Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09812-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:03:40Z","timestamp":1784286220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09812-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9812"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09812-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"504"}}